Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Vascular Comorbidities Worsen Prognosis of Patients with Heart Failure Hospitalized with COVID-19

View ORCID ProfileJacob Mok, Juan Malpartida, Kimberly O’Dell, Joshua Davis, Cuilan Gao, Harish Manyam
doi: https://doi.org/10.1101/2021.03.23.21254209
Jacob Mok
1The University of Tennessee Health Science Center College of Medicine Chattanooga, Internal Medicine Chattanooga, TN, USA (423) 778-2998
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jacob Mok
  • For correspondence: jmok1990@gmail.com
Juan Malpartida
1The University of Tennessee Health Science Center College of Medicine Chattanooga, Internal Medicine Chattanooga, TN, USA (423) 778-2998
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly O’Dell
1The University of Tennessee Health Science Center College of Medicine Chattanooga, Internal Medicine Chattanooga, TN, USA (423) 778-2998
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Davis
2UTHSC College of Medicine Chattanooga, Cardiovascular disease Chattanooga, TN, USA (423) 778-4465
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cuilan Gao
4The University of Tennessee at Chattanooga, Mathematics Chattanooga, TN, USA (423) 425-4554
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harish Manyam
2UTHSC College of Medicine Chattanooga, Cardiovascular disease Chattanooga, TN, USA (423) 778-4465
3Erlanger Health System, Heart and Lung Institute Chattanooga, TN, USA (423) 778-5661
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Prior diagnosis of heart failure (HF) is associated with increased length of hospital stay (LOS) and mortality from Coronavirus disease-2019 (COVID-19). Associations between substance use, venous thromboembolism (VTE), or peripheral arterial disease (PAD) and its effects on LOS or mortality in patients with HF hospitalized with COVID-19 remains unknown.

Objective This study identified risk factors associated with poor in-hospital outcomes among patients with HF hospitalized with COVID-19.

Methods Case control study was conducted of patients with prior diagnosis of HF hospitalized with COVID-19 at an academic tertiary care center from January 1, 2020 to February 28, 2021. Patients with HF hospitalized with COVID-19 with risk factors were compared with those without risk factors for clinical characteristics, length of stay (LOS), and mortality. Multivariate regression was conducted to identify multiple predictors of increased LOS and in-hospital mortality in patients with HF hospitalized with COVID-19.

Results Total of 211 HF patients were hospitalized with COVID-19. Females had longer LOS than males (9 days vs. 7 days; p < 0.001). Compared with patients without peripheral arterial disease (PAD) or ischemic stroke, patients with PAD or ischemic stroke had longer LOS (7 days vs. 9 days; p = 0.012 and 7 days vs. 11 days, p < 0.001; respectively). Older patients (aged 65 and above) had increased in-hospital mortality compared to younger patients (Adjusted OR: 1.04; 95% CI: 1.00 – 1.07; p = 0.036). VTE increased mortality more than three-fold in patients with HF hospitalized with COVID-19 (Adjusted OR: 3.33; 95% CI: 1.29 – 8.43; p = 0.011).

Conclusion Vascular diseases increase LOS and mortality in patients with HF hospitalized with COVID-19.

What is already known about this subject?

  • - Prior diagnosis of heart failure (HF) increases LOS and mortality in patients admitted to the hospital for COVID-19

  • - Antiplatelet, anticoagulation, and statin therapy decreased venous thromboembolism (VTE) in patients admitted for COVID-19

What does this study add?

  • - This study showed that patients with COVID-19, HF, and VTE had a higher mortality rate than patients with COVID-19 and either HF or VTE, or patients with HF and/or VTE who did not have COVID-19.

  • - This study showed that patients with HF hospitalized with COVID-19 had greater length of stay with prior diagnosis of peripheral arterial disease (PAD) or ischemic stroke

How might this impact on clinical practice?

  • - Our findings demonstrate clinical relevance by showing supportive evidence for antiplatelet, anticoagulation, and statin therapy in HF patients hospitalized with COVID-19

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no financial support for the research, authorship, and/or publication of this article.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

University of Tennessee at Chattanooga Institutional Review Board

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Juan.malpartida{at}erlanger.org, Kimberly.o'dell{at}erlanger.org, Joshua.davis{at}erlanger.org, Cuilan-gao{at}utc.edu, Harish.manyam{at}erlanger.org

Data Availability

Data are available within the article or its supplementary materials

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 26, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Vascular Comorbidities Worsen Prognosis of Patients with Heart Failure Hospitalized with COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Vascular Comorbidities Worsen Prognosis of Patients with Heart Failure Hospitalized with COVID-19
Jacob Mok, Juan Malpartida, Kimberly O’Dell, Joshua Davis, Cuilan Gao, Harish Manyam
medRxiv 2021.03.23.21254209; doi: https://doi.org/10.1101/2021.03.23.21254209
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Vascular Comorbidities Worsen Prognosis of Patients with Heart Failure Hospitalized with COVID-19
Jacob Mok, Juan Malpartida, Kimberly O’Dell, Joshua Davis, Cuilan Gao, Harish Manyam
medRxiv 2021.03.23.21254209; doi: https://doi.org/10.1101/2021.03.23.21254209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1238)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10021)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (752)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2280)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (536)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (157)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4833)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (491)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)